Isofundine

Magnesium chloride hexahydrate, potassium chloride, sodium chloride, calcium chloride dihydrate and malate, the active ingredients in Isofundine, are an electrolyte solution presented as an injectable solution for intravenous use. It restores electrolyte balance and plasma volume in patients with electrolyte depletion, such as hypokalemia, hyponatremia, hypocalcemia, and magnesium deficiency.

GNH USA supplies Isofundine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Isofundine is used to correct electrolyte disturbances and support fluid replacement in clinical settings. - Electrolyte depletion: restores normal levels of magnesium, potassium, sodium, and calcium. - Hypokalemia: increases serum potassium concentration. - Hyponatremia: raises plasma sodium concentration. - Hypocalcemia: supplies calcium ions to correct low calcium. - Magnesium deficiency: provides magnesium to normalize serum levels. - Fluid replacement: contributes to plasma volume expansion in patients requiring volume resuscitation.

Isofundine may be associated with adverse reactions typical of intravenous electrolyte solutions.

Common Side Effects: - Injection site pain: mild discomfort at the infusion site. - Hypernatremia: elevated sodium levels if administered excessively. - Hyperkalemia: increased potassium concentration leading to cardiac effects. - Hypercalcemia: raised calcium levels causing muscle weakness or arrhythmia. - Hypermagnesemia: excess magnesium resulting in hypotension or flushing.

Serious or Rare Side Effects: - Cardiac arrhythmia: abnormal heart rhythm due to electrolyte imbalance. - Severe hypotension: marked drop in blood pressure. - Allergic reaction: rash, itching, or anaphylaxis. - Metabolic alkalosis: shift in acid‑base balance. - Vascular thrombosis: clot formation at catheter site.

When using Isofundine, clinicians should observe specific precautions to minimize risks. - Renal impairment: adjust infusion rate and monitor serum electrolytes closely. - Cardiac disease: avoid rapid infusion that may provoke arrhythmias. - Fluid overload: assess volume status to prevent pulmonary edema. - Electrolyte monitoring: check serum levels before, during, and after administration. - Drug incompatibility: do not mix with calcium‑containing solutions unless compatibility is confirmed. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Isofundine can interact with other medications that affect electrolyte balance or cardiac conduction.

Major Interactions (Avoid): - Digoxin: increased risk of toxicity due to altered potassium levels. - Calcium channel blockers: additive effects on cardiac conduction when calcium levels rise. - Loop diuretics: may cause excessive electrolyte shifts if given concurrently.

Moderate Interactions (Monitor Closely): - ACE inhibitors/ARBs: monitor potassium to avoid hyperkalemia. - Beta‑blockers: watch for bradycardia if electrolyte disturbances occur. - Antacids containing magnesium or calcium: may increase total electrolyte load.